2024 Revenues ($USD) : $57.07B

Ranked #3 on the Pharma 50 list, Johnson & Johnson (NYSE: JNJ) reported full-year 2024 sales for its core pharmaceutical segment, Innovative Medicine, of $57.07 billion. This represents approximately 4.2% growth compared to $54.76 billion in 2023. The company's total revenue, including its MedTech division ($32 billion), reached $88.8 billion for the year. Headquartered in New Brunswick, NJ, J&J employed nearly 140,000 people globally (companywide) and held total assets of $180.10 billion at year-end.

Investment in R&D for the Innovative Medicine segment remained substantial at $13.53 billion in 2024, equating to 23.7% of the segment's sales, slightly higher than the 21.9% ratio in 2023.

Key strategic developments and pipeline updates included:

Finalization of the acquisition of Ambrx Biopharma, Inc. in early 2025 for approximately $2 billion. This move significantly bolsters J&J's oncology pipeline, particularly in the area of targeted Antibody Drug Conjugates (ADCs).

Positive results from the Phase 3b APEX study for TREMFYA (guselkumab) in adults with active psoriatic arthritis were announced in April 2025. The study met its primary endpoint for reducing disease signs/symptoms and its major secondary endpoint for reducing structural damage progression. J&J highlighted TREMFYA as the first IL-23 inhibitor demonstrating significant inhibition of structural damage progression in this patient group within a Phase 3b trial.